Comprehensive multiple risk factor control in cancer survivors to mitigate heart failure risk: insights from a prospective cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Holistic Management of Multiple Risk Factors in Cancer Survivors to Reduce Heart Failure Incidence: Findings from a Prospective Cohort Analysis

  • By

  • Yang-Wei Cai

  • Jing-Wei Gao

  • Mao-Xiong Wu

  • Ze-Gui Huang

  • Guang-Hong Liao

  • Chuan-Rui Zeng

  • Pin-Ming Liu

  • Yang-Xin Chen

  • Jing-Feng Wang

  • Hai-Feng Zhang

  • November 13, 2025

Share

  • 1

    Cancer survivors have a higher risk of heart failure compared to individuals without cancer, necessitating effective risk factor management.

  • 2

    Joint control of at least five modifiable risk factors in cancer survivors is associated with a 24% reduction in heart failure risk.

  • 3

    Each additional controlled risk factor correlates with a 12% decrease in heart failure risk among cancer survivors.

  • 4

    The study analyzed data from 14,466 cancer survivors and 57,864 matched controls from the UK Biobank over a median follow-up of 12.54 years.

  • 5

    Key risk factors for heart failure in cancer survivors include cancer type, chemotherapy, physical activity, smoking, and body mass index.

Original Source(s)

Comprehensive multiple risk factor control in cancer survivors to mitigate heart failure risk: insights from a prospective cohort study

  • by Yang-Wei Cai, Jing-Wei Gao, Mao-Xiong Wu, Ze-Gui Huang, Guang-Hong Liao, Chuan-Rui Zeng, Pin-Ming Liu, Yang-Xin Chen, Jing-Feng Wang, Hai-Feng Zhang

  • November 13, 2025

Related Content

Female patients less likely to receive invasive care

Review identifies recurring sex-based differences across specialties, including lower use of intensive and guideline-compliant treatment among female patients.

Circulating Dipeptidyl Peptidase 3 levels, an Antagonist of Angiotensin-(1–7), in Acute Heart Failure: Insights from the PUSH-AHF trial

Sodium Thiosulfate for Refractory Metabolic Alkalosis From Diuretic Therapy: A Case Series of Six Patients

  • September 1, 2026